Header

UZH-Logo

Maintenance Infos

Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance


Abstract

OBJECTIVE: We estimated and compared the risk of clinically identified acquired drug resistance under i) immediate initiation (the currently recommended ART initiation strategy), ii) initiation with CD4 < 500, and iii) initiation with CD4 < 350 cells/mm.
DESIGN: Cohort study based on routinely collected data from the HIV-CAUSAL Collaboration.
METHODS: For each individual, baseline was the earliest time when all eligibility criteria (ART-naïve, AIDS-free, and others) were met after 1999. Acquired drug resistance was defined using the Stanford classification as resistance to any antiretroviral drug that was clinically identified at least 6 months after ART initiation. We used the parametric g-formula to adjust for time-varying (CD4 count, HIV-RNA, AIDS, ART regimen and drug resistance testing) and baseline (calendar period, mode of acquisition, sex, age, geographical origin, ethnicity and cohort) characteristics.
RESULTS: In 50,981 eligible individuals, 10% had CD4 count>500 at baseline, and 63% initiated ART during follow-up. Of 2,672 tests for acquired drug resistance, 794 found resistance. The estimated 7-year risk (95% CI) of acquired drug resistance was 3.2% (2.8,3.5) for immediate initiation, 3.1% (2.7,3.3) for initiation with CD4 < 500, and 2.8% (2.5,3.0) for initiation with CD4 < 350 cells/mm. In analyses restricted to individuals with baseline in 2005-2015, the corresponding estimates were 1.9% (1.8, 2.5), 1.9% (1.7,2.4) and 1.8% (1.7,2.2).
CONCLUSIONS: Our findings suggest that the risk of acquired drug resistance is very low, especially in recent calendar periods, and that immediate ART initiation only slightly increases the risk. It is unlikely that drug resistance will jeopardize the proven benefits of immediate ART initiation.

Abstract

OBJECTIVE: We estimated and compared the risk of clinically identified acquired drug resistance under i) immediate initiation (the currently recommended ART initiation strategy), ii) initiation with CD4 < 500, and iii) initiation with CD4 < 350 cells/mm.
DESIGN: Cohort study based on routinely collected data from the HIV-CAUSAL Collaboration.
METHODS: For each individual, baseline was the earliest time when all eligibility criteria (ART-naïve, AIDS-free, and others) were met after 1999. Acquired drug resistance was defined using the Stanford classification as resistance to any antiretroviral drug that was clinically identified at least 6 months after ART initiation. We used the parametric g-formula to adjust for time-varying (CD4 count, HIV-RNA, AIDS, ART regimen and drug resistance testing) and baseline (calendar period, mode of acquisition, sex, age, geographical origin, ethnicity and cohort) characteristics.
RESULTS: In 50,981 eligible individuals, 10% had CD4 count>500 at baseline, and 63% initiated ART during follow-up. Of 2,672 tests for acquired drug resistance, 794 found resistance. The estimated 7-year risk (95% CI) of acquired drug resistance was 3.2% (2.8,3.5) for immediate initiation, 3.1% (2.7,3.3) for initiation with CD4 < 500, and 2.8% (2.5,3.0) for initiation with CD4 < 350 cells/mm. In analyses restricted to individuals with baseline in 2005-2015, the corresponding estimates were 1.9% (1.8, 2.5), 1.9% (1.7,2.4) and 1.8% (1.7,2.2).
CONCLUSIONS: Our findings suggest that the risk of acquired drug resistance is very low, especially in recent calendar periods, and that immediate ART initiation only slightly increases the risk. It is unlikely that drug resistance will jeopardize the proven benefits of immediate ART initiation.

Statistics

Citations

Altmetrics

Downloads

23 downloads since deposited on 19 Dec 2017
23 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Infectious Diseases
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2018
Deposited On:19 Dec 2017 15:18
Last Modified:20 Feb 2018 08:57
Publisher:Lippincott Williams & Wilkins
ISSN:0269-9370
Additional Information:This is a non-final version of an article published in final form in AIDS. 2017 Nov 10. doi: 10.1097/QAD.0000000000001692. [Epub ahead of print], Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. ; Lodi S(1), Günthard HF, Dunn D, Garcia F, Logan R, Jose S, Bucher HC, Scherrer AU, Schneider MP, Egger M, Glass TR, Reiss P, van Sighem A, Boender TS, Phillips AN, Porter K, Hawkins D, Moreno S, Monge S, Paraskevis D, Simeon M, Vourli G, Sabin C, Hernán MA; HIV-CAUSAL Collaboration
OA Status:Green
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.1097/QAD.0000000000001692
PubMed ID:29135583

Download

Download PDF  'Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance'.
Preview
Content: Accepted Version
Language: English
Filetype: PDF
Size: 766kB
View at publisher